Feb 20 2026 This Week in Cardiology

EVOLUT Low Risk data, a provocative meta-analysis, DNR orders, targeted hypothermia, good news in HFpEF evidence, and GLP-1s as AF drugs are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only . To read a partial transcript or to comment, visit: I EVOLUT Low Risk 6-year Results and a 5-year Meta-Analysis of TAVR vs SAVR 6-Year Outcomes of TAVR vs SAVR EVOLUT Low Risk Trial at 2 years EVOLUT Low Risk Trial at 3 years EVOLUT Low Risk Trial at 4 years Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials TAVR vs SAVR 5-Year Outcomes - Systematic Review TAVR vs SAVR Updated Meta-Analysis of RCTs UK TAVI Trial Dr David Cohen on X II DNR in the Hospital Inadequate Documentation of Unilateral DNR Orders GeriPal Blog Unilateral DNR Orders III Yet another failure of Targeted Hypothermia 2-Year Follow-Up of TTM2 Trial TTM2 Trial IV Good news in HFpEF Evidence ALT-FLOW II Trial V GLP-1 as AF drugs Semaglutide as Adjunctive Therapy in Obesity-Related PAF You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. Questions or feedback, please contact news@medscape.net

You can listen to Feb 20 2026 This Week in Cardiology online on Radio and Podcast. Open the player on this page to stream the available audio.

Feb 20 2026 This Week in Cardiology is an episode from This Week in Cardiology by Medscape Podcasts.

This episode is 25:10 long.

This episode was published on Feb 20, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from This Week in Cardiology when more episodes are available from the podcast feed.